#USA #San Diego #Immuno-Oncology #Verismo Therapeutics #SynKIR

Verismo Therapeutics Showcases Innovative KIR-CAR Data at AACR 2026

Verismo Therapeutics, a trailblazer in immuno-oncology, is set to present groundbreaking findings at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place from April 17-22 in San Diego, California. The company will reveal significant advancements in its multi-chain KIR-CAR platform, specifically focusing on its lead candidates, SynKIR™-110 and SynKIR™-310. These advancements could redefine treatment strategies for solid tumors and blood cancers.

Key Highlights of the Presentations

During the AACR Annual Meeting, Verismo will deliver vital insights through three separate presentations, each showcasing critical data on its innovative KIR-CAR technologies:

1. Phase 1 Data for SynKIR™-110:
An oral late-breaking presentation will unveil the initial data from the STAR-101 clinical trial that evaluates SynKIR™-110 in patients with advanced solid tumors, including ovarian cancer, mesothelioma, and cholangiocarcinoma. According to Dr. Laura A. Johnson, Chief Scientific Officer at Verismo, this marks a pivotal transition from preclinical evidence to first-in-human results. The presentation will emphasize how SynKIR™-110 aims to overcome the limitations of current CAR T therapies, particularly regarding efficacy and durability of responses in challenging tumor environments.

2. Preclinical Data on SynKIR™-310:
A poster presentation will highlight preclinical and early clinical results from the CELESTIAL-301 trial, focusing on SynKIR™-310's performance in B cell non-Hodgkin lymphomas. Researchers will showcase how SynKIR™-310, significantly outperforming conventional treatments in preliminary studies, is poised to deliver promising responses in patients who have faced relapses or resistances to standard therapies.

3. EGFR-Targeted KIR-CAR in Glioblastoma:
The third vital presentation will introduce exciting preclinical data related to an EGFR-targeted multi-chain KIR-CAR therapy aimed at treating glioblastoma. This innovative approach combines the advantages of natural killer (NK) cell biology with advanced gene-engineering techniques to create a novel solution to tackle glioblastomas that have proven resistant to traditional therapies.

About the KIR-CAR Platform

Verismo is at the forefront of KIR-CAR technology, harnessing a multi-chain architecture designed to enhance the persistence and success of T cells in attacking tumors. Unlike traditional CAR T therapies that can become ineffective due to inherent signaling issues and tumor-induced immunosuppression, the KIR-CAR design capitalizes on a more natural immune response, potentially leading to better long-term outcomes for patients. This technology represents a significant stride forward, addressing substantial unmet medical needs in the treatment of advanced solid tumors and hematologic malignancies.

Conclusion: A New Era in Cancer Treatment

Verismo Therapeutics’ upcoming presentations at AACR 2026 symbolize a crucial step in revolutionizing cancer immunotherapy. With two investigational KIR-CAR therapies spotlighted, the company stands on the brink of introducing novel treatment paradigms aimed at delivering more effective patient outcomes against some of the most challenging cancers. As these discussions unfold, the scientific community eagerly anticipates how these innovations will shape the future landscape of oncology treatment.

About Verismo Therapeutics

Verismo Therapeutics operates under the banner of HLB Innovation, focusing on pioneering treatments that utilize novel multi-chain KIR-CAR technology. With clinical trials ongoing for SynKIR™-110 and SynKIR™-310, the company is committed to providing cutting-edge solutions to urgent healthcare challenges. For more information, visit Verismo Therapeutics Website.